株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

真性赤血球増加症後骨髄線維症 (PPV-MF) :世界の治験動向

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Global Clinical Trials Review, H2, 2015

発行 GlobalData 商品コード 342286
出版日 ページ情報 英文 89 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
真性赤血球増加症後骨髄線維症 (PPV-MF) :世界の治験動向 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Global Clinical Trials Review, H2, 2015
出版日: 2015年09月23日 ページ情報: 英文 89 Pages
概要

当レポートでは、真性赤血球増加症後骨髄線維症 (PPV-MF) の治療薬に関する治験について調査分析し、最新動向、段階別・相別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどについて、体系的な情報を提供しています。

目次

レポートガイダンス

地域別の治験

  • 国別の治験動向
    • アジア太平洋地域の主要国
    • 欧州の主要国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国における治験:血液疾患の治験に対する真性赤血球増加症後骨髄線維症 (PPV-MF) の割合

G7諸国における治験:相別

G7諸国における治験:段階別

E7諸国における治験:血液疾患の治験に対する真性赤血球増加症後骨髄線維症 (PPV-MF) の割合

E7諸国における治験:相別

E7諸国における治験:段階別

相別の治験

段階別の治験

評価項目別の治験

未完了の治験

一定期間に採用された被験者

スポンサータイプ別の治験

有望なスポンサー

  • 真性赤血球増加症後骨髄線維症 (PPV-MF) の治療薬の治験に参加している主要企業

有望薬

治験プロファイルの概要

付録

図表

目次
Product Code: GDHC2873CTIDB

GlobalData's clinical trial report, "Post-Polycythemia Vera Myelofibrosis (PPV-MF) Global Clinical Trials Review, H2, 2015" provides an overview of Post-Polycythemia Vera Myelofibrosis (PPV-MF) clinical trials scenario. This report provides top line data relating to the clinical trials on Post-Polycythemia Vera Myelofibrosis (PPV-MF). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Post-Polycythemia Vera Myelofibrosis (PPV-MF) to Hematological Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Post-Polycythemia Vera Myelofibrosis (PPV-MF) to Hematological Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials by Region, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015*
  • Proportion of Post-Polycythemia Vera Myelofibrosis (PPV-MF) to Hematological Disorders Clinical Trials, G7 Countries (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Post-Polycythemia Vera Myelofibrosis (PPV-MF) to Hematological Disorders Clinical Trials, E7 Countries (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*

List of Figures

  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015*
  • Proportion of Post-Polycythemia Vera Myelofibrosis (PPV-MF) to Hematological Disorders Clinical Trials, G7 Countries (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Post-Polycythemia Vera Myelofibrosis (PPV-MF) to Hematological Disorders Clinical Trials, E7 Countries (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top